ATAI Life Sciences N.V. Forecast, price target & analysts
ATAI Life Sciences N.V. Target price 2026 - Analyst rating & recommendation
ATAI Life Sciences N.V. Classifications & Recommendation
ATAI Life Sciences N.V. Price Target
| Target Price | $8.16 |
| Price | $7.35 |
| Potential |
11.02%
register free of charge
|
| Number of Estimates | 13 |
|
13 Analysts have issued a price target ATAI Life Sciences N.V. 2027 .
The average ATAI Life Sciences N.V. target price is $8.16.
This is
11.02%
register free of charge
$16.80
128.57%
register free of charge
$6.82
7.24%
register free of charge
|
|
| A rating was issued by 21 analysts: 7 Analysts recommend ATAI Life Sciences N.V. to buy, 14 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the ATAI Life Sciences N.V. stock has an average upside potential 2027 of
11.02%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 4.09 | 2.68 |
| 1,219.35% | 34.50% | |
| EBITDA Margin | -2,695.60% | -5,792.95% |
| 91.59% | 114.90% | |
| Net Margin | -16,138.14% | -5,904.05% |
| 66.48% | 63.42% |
17 Analysts have issued a sales forecast ATAI Life Sciences N.V. 2026 . The average ATAI Life Sciences N.V. sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an ATAI Life Sciences N.V. EBITDA forecast 2026. The average ATAI Life Sciences N.V. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
16 ATAI Life Sciences N.V. Analysts have issued a net profit forecast 2026. The average ATAI Life Sciences N.V. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.91 | -0.43 |
| 212.90% | 85.22% | |
| P/E | negative | |
| EV/Sales | 933.20 |
16 Analysts have issued a ATAI Life Sciences N.V. forecast for earnings per share. The average ATAI Life Sciences N.V. EPS is
This results in the following potential growth metrics and future valuations:
ATAI Life Sciences N.V....
Current ATAI Life Sciences N.V. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Deutsche Bank |
Locked
➜
Locked
|
Locked | Aug 12 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jul 20 2026 |
| Jefferies |
Locked
➜
Locked
|
Locked | Jul 17 2026 |
| Jones Trading |
Locked
➜
Locked
|
Locked | Jul 17 2026 |
| Maxim Group |
Locked
➜
Locked
|
Locked | Jul 16 2026 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Jul 16 2026 |
| Needham |
Locked
➜
Locked
|
Locked | Jul 16 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Deutsche Bank:
Locked
➜
Locked
|
Aug 12 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jul 20 2026 |
|
Locked
Jefferies:
Locked
➜
Locked
|
Jul 17 2026 |
|
Locked
Jones Trading:
Locked
➜
Locked
|
Jul 17 2026 |
|
Locked
Maxim Group:
Locked
➜
Locked
|
Jul 16 2026 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Jul 16 2026 |
|
Locked
Needham:
Locked
➜
Locked
|
Jul 16 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
